J9334 – Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc
HCPCS Level II code · J codes: Drugs Administered Other Than Oral Method
HCPCS codeJ9334
- Long description
- Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc
- Short description
- Inj efgart-alfa 2mg hya-qvfc
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1DChemotherapy- ASC
- Approved for ambulatory surgical centers
- Added
- January 1, 2024
- Last change
- January 1, 2024 – No change
Frequently asked questions
What is HCPCS code J9334?
J9334 is a HCPCS Level II code for injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc.
Does Medicare cover J9334?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby J codes
- J9325 – Injection, talimogene laherparepvec, per 1 million plaque forming units
- J9326 – Injection, telisotuzumab vedotin-tllv, 1 mg
- J9328 – Injection, temozolomide, 1 mg
- J9329 – Injection, tislelizumab-jsgr, 1mg
- J9330 – Injection, temsirolimus, 1 mg
- J9331 – Injection, sirolimus protein-bound particles, 1 mg
- J9332 – Injection, efgartigimod alfa-fcab, 2mg
- J9333 – Injection, rozanolixizumab-noli, 1 mg
- J9340 – Injection, thiotepa, 15 mg
- J9341 – Injection, thiotepa (tepylute), 1 mg
- J9342 – Injection, thiotepa, not otherwise specified, 1 mg
- J9345 – Injection, retifanlimab-dlwr, 1 mg
- J9347 – Injection, tremelimumab-actl, 1 mg
- J9348 – Injection, naxitamab-gqgk, 1 mg
- J9349 – Injection, tafasitamab-cxix, 2 mg
- J9350 – Injection, mosunetuzumab-axgb, 1 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.